Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256S214

chronic GVHD occurred in 37.5% of evaluable patients. Fourpatients relapsed and died, 3/4 who were not in chronicphase at the time of transplant. No patient died of treatment-related mortality. 71% of patients transplanted in secondchronic phase remained in molecular remission at the lastfollow-up. After a median follow-up of 22 months medianPFS had not been reached; 6 patients (60%) are alive, 5 are incomplete molecular remission and one with low level PCRpositivity (Figure 1).Conclusion: Our results suggest that HaploSCT can producedurable complete remissions with minimal toxicity for pa-tients with advanced CML, and that treatment outcomes arecomparable with matched transplantation as recently re-ported by us in abstract format by Ahmed et al. Largerstudies, with longer follow-up and comparison to otherdonor sources are needed to better assess this approach.

326Safety of Stem Cell Mobilization in Donors with SickleCell TraitMurtadha Al-Khabori 1, Fahad Al-Ghafri 1, Salam Al-Kindi 1,Arwa Z Al-Riyami 1, Khalil Al-Farsi 1, Mohammed Al-Huneini 1,David Dennison 1, Abdulhakim Al-Rawas 2, Shahina Daar 1.1 Hematology, Sultan Qaboos University Hospital, Muscat,Oman; 2 Child Health, Sultan Qaboos University Hospital,Muscat, Oman

Introduction: The safety of stem cell mobilization using highdose granulocyte-colony stimulating factor has not beenestablished in stem cell donors with sickle cell trait (SCT).Herein, we aimed to estimate the incidence of adverse eventsrelated to stem cell mobilization in donors with SCT incomparison to normal donors.Methods: In this retrospective matched case control study,we enrolled 12 consecutive stem cell transplant donors withSCT (cases) and 12 age and gender matched donors withnormal Hemoglobin electrophoresis (controls) betweenJanuary 2007 and May 2013. We reviewed the health recordsfor reported adverse events. We compared the incidence ofadverse events using the appropriate statistical tests. We usefilgrastim 10 microgram/kg subcutaneously daily for 6 daysand collect the peripheral blood stem cells on day 6 after 2hours of the last filgrastim dose.Results: Both groups had similar baseline characteristics.There were 6 males and 6 females in each group, with meanage of 17 years in SCT donors and 19 years in non-SCT donors.The mean weight was 57 and 63 Kg for SCT and non-SCTdonors respectively. There was no statistically significantdifference between the two groups in the reported adverseevents including bone pain, headache, myalgia and para-sthesia. In the SCT donors group, three donors had headache,one had bone pain and one had parasthesia. In the non-SCTcontrol group, two donors had headache, two had bone painand one had myalgia. None of donors had chest pain, sei-zures, bleeding, nausea, vomiting, infection, splenic rupture,carpal-tunnel syndrome or blood transfusion. There were noreported deaths. The mean CD34 positive cell countmeasured on day 6 of mobilization was 98.2 x 106 /L (+/-87.10) in the SCT group compared to 81.87 x 106 /L (+/- 78.71)in the non-SCT control group (P¼0.81).Conclusion: The observed incidence of adverse events inSCT-donors in relation to stem cell mobilization is very low,and is not higher than in non-SCT donors. Donors with SCTcan be considered for stem cell mobilization. However, pro-spective and larger studies are needed to confirm the safetyof stem cell mobilization in this group.

327An Assessment of the Outcomes of Second DonationRequests through the Canadian Blood Services OnematchUnrelated RegistryIain Patrick Arseneau Jr. 1, Stephen Couban 2, Monelle Ross 3,Kara Thompson 4, Meagan Green 3, Beth Amer 3,Chris Theriault 4, Mindy Goldman 3, Sudeep Shivakumar 4.1 Dalhousie University, Halifax, NS, Canada; 2Medicine, QEIIHealth Sciences Centre, Halifax, NS, Canada; 3 Canadian BloodServices, Ottawa, ON, Canada; 4 Department of Medicine,Capital District Health Authority, Halifax, NS, Canada

Introduction: Allogeneic transplants using hematopoieticstem cells from unrelated donors (alloHSCT) have becomemore common than related transplants. Matched unrelatedalloHSCT in Canada are facilitated by the OneMatch StemCell and Marrow Network. Patients may undergo a secondunrelated alloHSCT with prior conditioning or simplyreceive an infusion of cells from an unrelated donor [donorlymphocyte infusion (DLI)]. There have been few studiesexamining the outcomes of second unrelated alloHSCT orDLI in large numbers of patients and none involving theCanadian registry.Methods: We examined a consecutive series of Canadianpatients who received a second unrelated alloHSCT or DLIthrough OneMatch during the period between January 1st

2002 and December 31st 2011. We collected informationabout disease type and status at the time of first trans-plant, first transplant date, indication for and date of sec-ond transplant or DLI, and the graft types (bone marrow,G-CSF stimulated peripheral blood or unstimulated DLI)and conditioning regimens for both transplants. Survivalstatus, disease status, and engraftment status at mostrecent follow-up were also collected. Donor and recipientinformation including year of birth and weight was alsocollected.Results: There were 128 consecutive Canadian patients whoreceived a second unrelated alloHSCT or DLI during theperiod specified. Median age of recipients was 37 (range:2-68). There were 73 males, 36 females, and 19 patientswhose sex was unknown. The most common indication forsecond transplant or DLI was disease relapse (n¼68, 53%),followed by graft failure (n¼37, 29%). The most commondisease for which the first transplant was undertaken wasacute myeloid leukemia (n¼37, 29%), followed by lympho-proliferative disorders (n¼29, 23%). The most common grafttype for second transplant was unstimulated peripheralblood (65, 51%), and 101 of 128 (79%) second transplantsused the same donor as for the first transplant. Mediansurvival was 1.03 years (95% CI ¼ 0.87-1.69). Median timebetween transplants was 10.56 months (0.6-105.72).Patients whose time between transplants was above themedian were more likely to be alive at last follow-up,(p¼0.029) and they exhibited higher survival in the firstyear post-transplant. No other factors were found to sig-nificantly affect survival.

This study is the first to examine a consecutive series ofunselected patients receiving a second donation of hemato-poietic stem cells from an unrelated donor using the Cana-dian registry. Survival is comparable to previous studiesusing the American (Schriber et al., 2010) and German(Platzbecker et al., 2008) registries. This study shows thatoutcomes do not differ significantly based on disease, age,gender, conditioning regimen, and graft type. Further studieswill be needed to identify factors that better predict out-comes when utilizing this scarce resource.